Additionally, PD-L1+ EVs produced by cancer cells are a prominent mechanism of immunotherapy resistance by acting as off-target decoys for αPD-1 monoclonal antibodies that are used to reinvigorate anti-tumour T cell immunity [209]. This evidence concerns the gene CD274 and cancer.